← Back to headlines
Eli Lilly's Strategy: Building an Obesity Empire Beyond Zepbound
Eli Lilly is reportedly not just replacing its drug Zepbound but is actively expanding its presence to build a dominant position in the broader obesity treatment market.
11 Apr, 14:50 — 11 Apr, 14:50
Sources
Showing 1 of 1 sources
Related Stories
Banks Pause Sales of Products Linked to Mark Walter Amid Investigations
34m ago
Rating Agencies Maintain Stable Outlooks for French and Portuguese Sovereign Debt
38m ago
Canada’s Economy Rebounds With 3.3% Growth in Second Quarter
1h ago
Walmart Reaches Settlement With U.S. Government Over Opioid Crisis
1h ago